A phase 3 trial published in The Lancet HIV found that a single-tablet combination of bictegravir and lenacapavir (BIC/LEN) is noninferior to complex antiretroviral therapy (ART) for virologically suppressed HIV-1 patients. The ARTISTRY-2 study suggests this single-tablet regimen could simplify daily treatment protocols and improve adherence.
What did the ARTISTRY-2 trial find?
The ARTISTRY-2 trial demonstrated that switching to a 75-50 mg BIC/LEN single-tablet formulation is noninferior to continuing a complex 50-200-25 mg BIC/FTC/TAF regimen. According to Infectious Disease Advisor, the study met its primary outcome, which measured the proportion of participants with HIV-1 RNA levels of at least 50 copies/mL at week 48.
Researchers established noninferiority using a 4% margin. The double-blind, randomized, controlled, phase 3 trial involved 574 people with HIV (PWH) across 14 countries. All participants recruited for the study had already achieved viral suppression while using single-tablet BIC/FTC/TAF.
How do the two treatment regimens compare?
The study compared a newer single-tablet option against a standard complex regimen. Participants were randomly assigned in a 2:1 ratio to either the new combination or the existing treatment. The following data summarizes the regimens used in the ARTISTRY-2 trial:
| Regimen Component | BIC/LEN (Single-Tablet) | BIC/FTC/TAF (Complex ART) |
|---|---|---|
| Dosage (mg) | 75-50 mg | 50-200-25 mg |
| Primary Outcome Goal | Noninferiority within a 4% margin | |
How does single-tablet therapy affect HIV management?
Simplifying medication regimens is a major focus in HIV clinical care. Infectious Disease Advisor reports that moving from complex, multi-pill regimens to single-tablet formulations can lead to better quality of life for patients. By reducing the daily pill burden, healthcare providers aim to minimize the risk of missed doses.
The findings from the ARTISTRY-1 trial previously indicated that switching to single-tablet BIC/LEN was noninferior to remaining on complex ART. This supports the broader trend of clinical efforts to streamline therapy for those who have already achieved viral suppression.
For more technical details, you can view the study registration via ClinicalTrials.gov (NCT06333808).
Answer: According to the ARTISTRY-1 study results, switching to single-tablet BIC/LEN was found to be noninferior to staying on complex ART.
Frequently Asked Questions
What was the primary goal of the ARTISTRY-2 trial?
The trial aimed to assess the noninferiority of the single-tablet BIC/LEN regimen compared to the BIC/FTC/TAF regimen in people with HIV-1 who were already virologically suppressed.
Who participated in the study?
The study included 574 people with HIV (PWH) across 14 different countries.
What is the definition of noninferiority used in this study?
Noninferiority was defined by a margin of 4% regarding the proportion of individuals with HIV-1 RNA of at least 50 copies/mL at week 48.
Stay informed on the latest developments in infectious disease research. Subscribe to our newsletter or leave a comment below to share your thoughts on these clinical trial results.
